Ransom Advisory Ltd Takes $988,000 Position in Eli Lilly and Company $LLY

Ransom Advisory Ltd acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,196 shares of the company’s stock, valued at approximately $988,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Aspen Investment Management Inc grew its stake in shares of Eli Lilly and Company by 5.0% during the first quarter. Aspen Investment Management Inc now owns 973 shares of the company’s stock valued at $804,000 after buying an additional 46 shares during the last quarter. Ilmarinen Mutual Pension Insurance Co boosted its holdings in shares of Eli Lilly and Company by 4.1% during the first quarter. Ilmarinen Mutual Pension Insurance Co now owns 127,600 shares of the company’s stock worth $105,386,000 after purchasing an additional 5,000 shares during the period. Advisory Alpha LLC boosted its holdings in shares of Eli Lilly and Company by 11.1% during the first quarter. Advisory Alpha LLC now owns 4,168 shares of the company’s stock worth $3,442,000 after purchasing an additional 417 shares during the period. Alaethes Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 3.6% during the first quarter. Alaethes Wealth LLC now owns 4,233 shares of the company’s stock worth $3,496,000 after purchasing an additional 148 shares during the period. Finally, SCS Capital Management LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth about $5,326,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $749.99 on Wednesday. The company has a market capitalization of $709.84 billion, a P/E ratio of 49.02, a price-to-earnings-growth ratio of 1.03 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a 50 day moving average of $742.49 and a 200 day moving average of $779.42. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $942.35.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company’s dividend payout ratio (DPR) is 39.22%.

Analyst Ratings Changes

A number of research firms have recently weighed in on LLY. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Guggenheim dropped their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Finally, Leerink Partners reiterated a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $950.17.

Insider Activity at Eli Lilly and Company

In related news, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jamere Jackson purchased 200 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was purchased at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock valued at $2,894,841 over the last ninety days. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.